CHU [CHINA UNICOM (HONG KONG)] 20-F: Chu Ka Yee Telephone: +852 2121 3220 Facsimile:

[Chu Ka Yee Telephone: +852 2121 3220 Facsimile: +852 2121 3232 th 75 99 Queen’s Road Central Hong Kong (Name, Telephone, E-mail and/or Facsimile Number and Address of Company Contact person) Title of Each Class Name of Each Exchange On Which Registered Ordinary shares * None (Title of class) None (Title of Class) Indicate the number of outstanding shares of]

By | 2016-03-15T01:19:44+00:00 April 23rd, 2015|Categories: Chinese Stocks, CHU, Webplus ver|Tags: , , , , , |0 Comments

NPD [China Nepstar Chain Drugstore] 20-F: (Original Filing)

[CHINA NEPSTAR CHAIN DRUGSTORE LTD. Table of Contents Page PART I ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3.] [ENTRUSTMENT LOAN AGREEMENT (For Corporate Business) Tian An 0020 Serial No.: Xing Yin Shen Shenzhen Nepstar Pharmaceutical Co., Ltd. Entrustor: A-15B, Shenzhen Nanshan District Haiwang Building Domicile: Zhang Simin Legal Representative/Principal Officer: Shenzhen Nanshan District Haiwang Building A-15B Mailing Address: 518000 Postal Code: ____ 26430133 Telephone Number: _ Shenzhen Tian’an Branch of Industrial Bank Co., Ltd. (the “Bank”) Lender: Suite] [ENTRUSTMENT LOAN AGREEMENT (For Corporate Business) Tian An 0019 Serial No.: Xing Yin Shen Shenzhen Nepstar Pharmaceutical Co., Ltd. Entrustor: A-15B, Shenzhen Nanshan District Haiwang Building Domicile: Zhang Simin Legal Representative/Principal Officer: Shenzhen Nanshan District Haiwang Building A-15B Mailing Address: 518000 Postal Code: ____ 26430133 Telephone Number: _ Shenzhen Tian’an Branch of Industrial Bank Co., Ltd. Lender: Suite 101, Tower] [SUBSIDIARIES OF THE COMPANY Wholly-owned subsidiaries, each of which is duly incorporated in the PRC: • Shenzhen Nepstar Pharmaceutical Electronic Technologies Ltd. • Shenzhen Nepstar Commerce Development Ltd. • Shenzhen Jinfu Logistics Service Co., Ltd. • Shenzhen Wisconsin Trading Development Co., Ltd. • Shenzhen Nepstar Pharmaceutical Co., Ltd. Consolidated entities, each of which is duly incorporated in the PRC: •] [Certification by the Chief Executive Officer Sarbanes-Oxley Act of 2002 I, Fuxiang Zhang, certify that: 1. I have reviewed this annual report on Form 20-F of China Nepstar Chain Drugstore Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [Certification by the Chief Financial Officer Sarbanes-Oxley Act of 2002 I, Zixin Shao, certify that: 1. I have reviewed this annual report on Form 20-F of China Nepstar Chain Drugstore Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [Certification by the Chief Executive Officer Sarbanes-Oxley Act of 2002 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Fuxiang Zhang Chief Executive Officer] [Certification by the Chief Financial Officer Sarbanes-Oxley Act of 2002 1. 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Zixin Shao Chief Financial Officer] [Consent of Independent Registered Public Accounting Firm To the Board of Directors China Nepstar Chain Drugstore Ltd.: We consent to the incorporation by reference in the registration statement (No. 333-147702) on Form S-8 of China Nepstar Chain Drugstore Ltd. of our reports dated April 23, 2015, with respect to the consolidated balance sheets of China Nepstar Chain Drugstore Ltd. and] [April 23, 2015 China Nepstar Chain Drugstore Ltd. 25F, Neptunus Yinhe Keji Building No.1, Kejizhong 3rd Road Nanshan District, Shenzhen Guangdong Province 518057 People's Republic of China Dear Sir/Madam: Annual Report SEC We hereby consent to the reference of our name and inclusion of the summary and quotation of our opinion under the headings “ITEM 1A. RISK FACTORS” and “ITEM]

Skip to toolbar